©2024 Stanford Medicine
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
Not Recruiting
Trial ID: NCT04911478
Purpose
The purpose of this study is to assess long-term side effects from subjects who receive an
Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent
interventional study. No additional study drug will be given, but subjects can receive other
therapies for their cancer while they are being followed for long term safety in this study.
For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell
product, subjects will be assessed for long-term safety and survival through collection of
data that include safety, efficacy, pharmacokinetics and immunogenicity.
Official Title
Long-term Follow-up Protocol for Subjects Treated With Adicet Allogeneic Gamma Delta (γδ) CAR T Cell Investigational Products
Stanford Investigator(s)
David Miklos
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:
- All patients who received any Adicet allogeneic CAR T investigational product and have
either completed the core treatment protocol or have discontinued early
- All patients who are willing and able to adhere to the study visit schedule and other
protocol requirements.
- Capable of giving signed informed consent which includes compliance with requirements
and restrictions listed in the informed consent form (ICF) and protocol
Exclusion Criteria:
- There are no specific exclusion criteria for this study
Intervention(s):
genetic: ADI-001
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
David Miklos, MD
650-723-0822